| 摘要 |
In various aspects, the invention provides for the humanization of the rat anti-beta7 integrin subunit monoclonal antibody FIB504, inhibition by such humanized antibodies of the binding of beta7 subunit-containing integrins to their ligands, and use of such antibodies in the treatment of certain disorders including, for example, inflammatory bowel disease, Crohn's disease, ulcerative colitis and other inflammatory disorders. |
